Posted by Michael Wonder on 02 Nov 2022
ICER publishes evidence report on gene therapies for haemophilia A and B
2 November 2022 - Duration of benefit with gene therapies and risks for rare side effects remain major uncertainties.
The ICER today posted its revised Evidence Report assessing the comparative clinical effectiveness and value of etranacogene dezaparvovec (CSL Behring) for haemophilia B. ICER also updated the previous haemophilia A assessment on valoctocogene roxaparvovec (Roctavian, BioMarin).
